- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01099228
Combination Targeted Radiotherapy in Neuroendocrine Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
RESEARCH PLAN / BACKGROUND AND SIGNIFICANCE:
Tumors originating from the neuroendocrine system, although relatively rare, may be life threatening. In cases where the disease has metastasized, the 5 year survival is very poor. 131I meta-iodobenzylguanidine (MIBG)and 90Y DOTA-D-Phe1-Tyr3-Octreotide (DOTATOC) are two radiopharmaceuticals that have shown promise as therapeutic agents in patients with metastatic neuroendocrine tumors. However, delivering sufficient radiation dose to the tumor to obtain objective anti-tumor responses or cure with these radiopharmaceuticals is challenging because of the allowable dose limits imposed by radiation damage to normal tissues. Organ biodistribution and kinetics of 90Y DOTATOC and 131I MIBG are substantially different, which leads to different critical organs for these agents, the kidney for Y90Y DOTATOC and the red marrow for 131I MIBG. We propose to investigate a mechanism to increase the radiation dose delivered to tumors without exceeding "critical" radiation dose to normal organs by combining 90Y DOTATOC and 131I MIBG.
AIMS / OBJECTIVES:
The primary aim of this project is to determine, what fraction of individuals with neuroendocrine tumors would show substantially improved tumor dosimetry with combined agent therapy compared to "best" single agent therapy and determine the magnitude of the potential tumor radiation dose increase.
METHODS:
To achieve this, we plan to perform serial scintigraphic imaging procedures to measure patient specific bone marrow, kidney, and tumor biodistribution and kinetics for 111In Pentetreotide and 131I-MIBG in adults and children with neuroendocrine tumors. Then, using the program we have already developed, we will input the individual dosimetry measures for bone marrow, kidney and tumor to determine the optimal amounts of administered radioactivity for the combination of 131I MIBG plus 90Y DOTATOC or 131I MIBG alone.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa
-
Iowa City, Iowa, United States, 52246
- Department of Veteran Affairs Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects with biopsy-proven metastatic (soft tissue) neuroendocrine tumors.
- Subjects with a Southwest Oncology Group (SWOG) performance score of 0-2 and an expected median survival of at least 6 months.
- The subject is able and willing to comply with study procedures and a signed and dated informed consent is obtained.
- Subjects must be >18 years of age
Exclusion Criteria:
- Subjects who use medications that are known to interfere with MIBG uptake and is unable to discontinue for medical reasons.
- Prior chemotherapy, radiotherapy or any investigational drugs within 60 days prior admission into this study. Patients must have recovered from all therapy-related toxicities
- Renal insufficiency with a serum creatinine 2 X ULN
- Subjects unable to lie still for the imaging studies.
- Subjects who because of their weight and body distribution do not fit into the imaging machine.
- Subjects receiving Sandostatin LAR < 21 days prior to dosing or Sandostatin Immediate Release (IR) < 24 hours prior to dosing.
- Female patients who are pregnant or breast feeding. Women of childbearing potential must have a negative serum/urine pregnancy test within 48 hours prior to administration of study treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 131-I MIBG and 111I-n pentetreotide
|
Subjects will receive 131I MIBG and 111In pentetreotide(surrogate for Y90-DOTATOC)
|
Active Comparator: 131-I MIBG and In-111 DOTATATE
|
131I MIBG and In-111 DOTATATE (surrogate for 177Lu DOTATATE)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dosimetry Results
Time Frame: 1 week after scan
|
Determine the patient specific bone marrow, kidney and tumor dosimetry results for each subject from the 2 groups will be used to calculate the optimal combination of administered activities for 131I-MIBG plus 90Y-DOTATOC (group 1) 131I-MIBG plus 177Lu-DOTATATE (group 2) and the resultant dose delivery to tumor from each combination
|
1 week after scan
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Radiation Dose
Time Frame: 3 months
|
Calculate the optimal amount for either agent when administered individually along with corresponding tumor radiation dose to determine the amount of each product will give maximum tumor kill and not damage other vunerable organs..
|
3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David Bushnell, M.D., University of Iowa; Veteran Affairs
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 200602763
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuroendocrine Tumors
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Gastroenteropancreatic Neuroendocrine TumorChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingAdvanced Gastroenteropancreatic Neuroendocrine Tumor
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingNeuroendocrine Tumors,GastroenteropancreaticTaiwan
-
Grupo Espanol de Tumores NeuroendocrinosActive, not recruitingNeuroendocrine Tumors | Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine TumorSpain
-
Australasian Gastro-Intestinal Trials GroupCompletedMidgut Neuroendocrine Tumours | Pancreatic Neuroendocrine TumoursAustralia
-
Amr Mohamed MDNovatek PharmaceuticalsRecruitingNeuroendocrine Carcinoma | Gastroenteropancreatic Neuroendocrine Tumor | Gastroenteropancreatic Neuroendocrine Neoplasm | Mixed Neuroendocrine-Non Neuroendocrine NeoplasmUnited States
-
Francesco De CobelliCompleted
-
TaiRx, Inc.Active, not recruitingNeuroendocrine Tumors | Gastro-enteropancreatic Neuroendocrine Tumor | Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor | Lung Neuroendocrine NeoplasmTaiwan
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingNeuroendocrine Tumors | Liver-Dominant Metastatic Pancreatic Neuroendocrine TumorsUnited States
-
University Hospital, Basel, SwitzerlandSwiss National Science Foundation; Paul Scherrer Institute (PSI)RecruitingNeuroendocrine Neoplasia's (NENs) | Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)Switzerland
Clinical Trials on 131-I MIBG and 111-In pentetreotide
-
MallinckrodtTerminated
-
John MarisAvailableNeuroblastoma | Childhood Metastatic PheochromocytomaUnited States
-
Jubilant DraxImage Inc.RecruitingNeoplasms | Neuroectodermal Tumors | NeuroblastomaUnited States
-
University of California, San FranciscoApproved for marketingPheochromocytoma | ParagangliomaUnited States
-
Jubilant DraxImage Inc.AvailableNeuroblastoma | Pheochromocytoma | ParagangliomaUnited States
-
Yale UniversityNational Cancer Institute (NCI)TerminatedKidney Cancer | Head and Neck Cancer | Lung Cancer | Brain and Central Nervous System Tumors | Intraocular Melanoma | Melanoma (Skin) | Pheochromocytoma | Islet Cell Tumor | Gastrointestinal Carcinoid Tumor | Neoplastic Syndrome | Neuroendocrine Carcinoma of the Skin | Childhood Langerhans Cell HistiocytosisUnited States
-
Radio Isotope Therapy of AmericaRadiomedix, Inc.; Excel Diagnostic Imaging Clinics; CHI St. Luke's Health, TexasCompletedNeuroendocrine TumorsUnited States
-
Molecular Insight Pharmaceuticals, Inc.CompletedPheochromocytoma | ParagangliomaUnited States
-
Sue O'DorisioNational Cancer Institute (NCI)CompletedNeuroendocrine Tumor | Neuroblastoma | Somatostatinoma | Adult Medulloblastoma | Childhood MedulloblastomaUnited States
-
Children's Hospital Medical Center, CincinnatiNo longer availableNeuroblastoma | Pheochromocytoma | ParagangliomaUnited States